首页>International journal of toxicology>Nonclinical safety profile of BMS-986001, a nucleoside transcriptase inhibitor for combination retroviral therapy
Nonclinical safety profile of BMS-986001, a nucleoside transcriptase inhibitor for combination retroviral therapy
作者单位:Research and Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, United States[1]Charles River Laboratories, Senneville, QC, Canada[2]Research and Development, Bristol-Myers Squibb Company, Mt Vernon, IN 47620, United States[3]